The study will enroll 500 consumers and 500 healthcare providers. The FDA will analyze their perceptions about certain fictional drug names for high cholesterol and gastroesophageal reflux disease.
For both conditions, participants will be presented with seven fictional drug names. Five will be names that may suggest the medical condition the drug is designed to treat and vary in terms of promise of effect. One will be a name that explicitly suggests efficacy or extreme value (the FDA provided “CureFlux” as an example), and one will be a neutral name.
Participants will answer questions about the names before and after the researchers tell them the drugs’ indications.
More articles on pharmacy:
Gilead, Merck co-developing long-acting HIV treatment
Roche to buy COVID-19 test maker for $1.8B
No link between AstraZeneca vaccine, blood clots, WHO says, despite countries halting use
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.